[The vaccine against poliomyelitis, inactivated, concentrated, injectable: analysis of ten years of use in tropical countries].
A new inactivated poliovirus vaccine of enhanced potency (N-IPV) has been developed since the late 70's. N-IPV can be produced on a large scale in industrial tanks. N-IPV has been extensively studied on all continents and under different climates, specially in tropical countries. It is presently included in vaccination programs of several african regions. N-IPV is recommended in infants as soon as 6 to 8 weeks of age, following a schedule including a primary vaccination with 2 doses at 2 months interval. N-IPV is usually combined to DPT in a quadruple form (DPTPolio). The characteristics and performances of N-IPV make it a substitute or a complement to oral poliovirus vaccine for use in the Expanded Program on Immunization, specially in the perspective of the goal of global poliovirus eradication.
Drucker
J
J
Laboratoire de Santé publique, Faculté de Médecine, Tours, France.
D000914:Antibodies, Viral / Q000097:blood; D014943:Global Health; D006801:Humans; D017955:Poliovirus / Q000276:immunology; D011054:Poliovirus Vaccine, Inactivated / Q000276:immunology / Q000592:standards*; D014329:Tropical Climate; D014611:Vaccination
D000914:Antibodies, Viral; D011054:Poliovirus Vaccine, Inactivated
Le vaccin contre la poliomyélite, inactivé, concentré, injectable: analyse de dix années d'utilisation dans les pays tropicaux.